This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
by Zacks Equity Research
Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
by Zacks Equity Research
Geron (GERN) misses earnings and sales estimates in Q4. However, revenues almost double year over year. Imetelstat remains in focus.
Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.
Alexion (ALXN) Gains On Positive Date From Lead Candidate
by Zacks Equity Research
Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress
by Zacks Equity Research
Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.
Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y
by Zacks Equity Research
Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.
Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug
by Zacks Equity Research
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2017.
AbbVie's Uterine Fibroids Candidate Succeeds in Phase III
by Zacks Equity Research
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up
by Zacks Equity Research
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Biogen to Buy Mid-Stage Neuropsychiatry Asset From Pfizer
by Zacks Equity Research
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Merrimack (MACK) reports narrower-than-expected loss in the fourth quarter due to lower operating expenses.
Aradigm Files MAA for Bronchiectasis Candidate in the EU
by Zacks Equity Research
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
Regeneron and Sanofi Announce Positive Data on Praluent
by Zacks Equity Research
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
Pfizer Gets FDA Panel Backing for New Indication for Xeljanz
by Zacks Equity Research
Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .
Corcept Plans Korlym Label Expansion, Pipeline in Progress
by Zacks Equity Research
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
Bayer, BASF in Talks for Vegetable Seeds Business Sell-Off
by Zacks Equity Research
Bayer (BAYRY) is in exclusive talks with BASF for the divestiture of its entire vegetable seeds business.
Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.
Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.
Lilly, Boehringer to Expand Jardiance Heart Failure Program
by Zacks Equity Research
Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.
Spectrum (SPPI) Q4 Loss Widens Y/Y, Sales Miss, Stock Falls
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the fourth quarter, while it misses on revenues. Rolontis successful in phase III study.
Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
by Zacks Equity Research
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.
Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Aduro (ADRO) reports narrower-than-expected loss in Q4. However, sales miss estimates and fall year over year on declining grant revenues.